Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visugromab + Immunochemotherapy in 1L Metastatic Non-Squamous NSCLC
NCT07098988Phase 2Recruiting
- Sponsor
- CatalYm
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of visugromab in non-small cell lung cancer (NSCLC), sponsored by CatalYm. Started Aug 2025; status: recruiting.
02
Drugs
visugromab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07098988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098988.